Gufic Biosciences Limited has re-appointed M/s. Poddar & Co. as its Cost Auditor and appointed Mrs. Saroj R. Kirdolia as the Internal Auditor for the financial year 2026-27. The Board of Directors approved these appointments at its meeting held on May 29, 2026, to ensure continued compliance with regulatory requirements and strengthen internal governance mechanisms.

Cost Auditor Re-appointment

The Board decided to re-engage M/s. Poddar & Co., Cost Accountants, as the Cost Auditors of the company for the upcoming financial year. The firm, led by proprietor Mr. Sandeep Poddar, brings 15 years of professional experience in cost and management accounting across diverse industries. M/s. Poddar & Co. has a track record of conducting statutory cost audits for clients in sectors including pharmaceuticals, chemicals, and infrastructure.

Internal Auditor Appointment

In a separate decision, the Board appointed Mrs. Saroj R. Kirdolia as the Internal Auditor of the company effective from the financial year 2026-27. Mrs. Kirdolia is a Chartered Accountant with over seven years of experience in auditing and taxation. She has been associated with the company for the past six years and is responsible for evaluating internal controls and business processes. Her tenure will continue until the cessation of her employment or until further decided by the Board.

Key Appointment Details

The following table summarizes the key particulars regarding the appointments:

The meeting, which commenced at 7.30 p.m. and concluded at 9.05 p.m., was conducted in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Gufic Biosciences Limited has announced that its board meeting is scheduled to be held on Friday, May 29, 2026. The meeting will be conducted pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Agenda for the Meeting

The primary agenda for the board meeting includes the consideration and approval of the audited financial results for the company. These results will cover both standalone and consolidated figures for the quarter and financial year ended March 31, 2026.

Additionally, the board will deliberate on recommending a final dividend on equity shares for the financial year 2025-26. Any dividend declared will be subject to the approval of shareholders at the ensuing Annual General Meeting.

Trading Window Closure

In continuation of the disclosure regarding the closure of the trading window dated March 27, 2026, the company has stated that the trading window shall remain closed. This restriction applies to all designated persons of the company along with their immediate relatives.

The closure is in accordance with the company's Code of Conduct for Prevention of Insider Trading, framed under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The window will remain shut until 48 hours after the declaration of the financial results.